Charles Schwab Investment Management Inc. Buys 52,204 Shares of Savara Inc (NASDAQ:SVRA)

Charles Schwab Investment Management Inc. grew its position in shares of Savara Inc (NASDAQ:SVRA) by 5.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 963,821 shares of the company’s stock after acquiring an additional 52,204 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Savara were worth $2,959,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of SVRA. Virtu Financial LLC bought a new position in Savara in the third quarter valued at about $67,000. BNP Paribas Financial Markets grew its stake in shares of Savara by 258.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after purchasing an additional 18,534 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Savara by 14.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after purchasing an additional 4,732 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Savara by 14.0% in the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock worth $158,000 after buying an additional 6,330 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Savara in the third quarter worth approximately $174,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SVRA has been the topic of several recent research reports. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company initiated coverage on Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.83.

Savara Stock Up 3.0 %

Shares of SVRA stock opened at $2.78 on Friday. The company has a market capitalization of $477.10 million, a price-to-earnings ratio of -6.47 and a beta of 0.60. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The company’s fifty day moving average price is $2.72 and its 200-day moving average price is $3.27. Savara Inc has a one year low of $2.26 and a one year high of $5.34.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.